GSK189254A
CAS No. 720690-73-3
GSK189254A ( GSK189254 )
Catalog No. M24731 CAS No. 720690-73-3
GSK189254A is a potent and specific histamine H3 receptor antagonist (pKi values: 9.59-9.90 and 8.51-9.17 for human and rat H3).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 77 | In Stock |
|
10MG | 113 | In Stock |
|
50MG | 332 | In Stock |
|
100MG | 478 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK189254A
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK189254A is a potent and specific histamine H3 receptor antagonist (pKi values: 9.59-9.90 and 8.51-9.17 for human and rat H3).
-
DescriptionGSK189254A is a potent and specific histamine H3 receptor antagonist (pKi values: 9.59-9.90 and 8.51-9.17 for human and rat H3).
-
SynonymsGSK189254
-
PathwayGPCR/G Protein
-
TargetHistamine Receptor
-
RecptorMouse H3 receptor;Human H3 receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number720690-73-3
-
Formula Weight351.4
-
Molecular FormulaC21H25N3O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:24 mg/mL (68.29 mM; Need ultrasonic)
-
SMILESCNC(=O)C1=CN=C(C=C1)OC2=CC3=C(CCN(CC3)C4CCC4)C=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Medhurst AD, et al. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther. 2007 Jun;321(3):1032-45.
molnova catalog
related products
-
Bepotastine Besilate
Bepotastine is a non-sedating, selective antagonist of histamine 1 (H1) receptor with pIC50 of 5.7.
-
Cimetidine
Cimetidine is a histamine-2 (H2) receptor antagonist.
-
Clobenpropit dihydro...
Clobenpropit dihydrobromide is a potent ?antagonist and inverse agonist of histamine H3R (histamine H3LR,pEC50 of 8.07)Clobenpropit inhibited cell migration and increased apoptosis of pancreatic cancer cells in combination with gemcitabine.?